Page results
-
Information about the autogenic training service at the Royal London Hospital for Integrated Medicine.
-
Information about total penectomy and perineal urethrostomy for patients referred to UCLH.
-
The UCLH immunotherapy-neurotoxicity multidisciplinary service (IO-neurotox MDT) was established collaboratively between the National Hospital for Neurology and Neurosurgery (NHNN) and a nationwide oncology clinical team to offer high-quality diagnostic and management guidance on the care of cancer patients with, or suspected of having, any form of neurological complication of immunotherapy (immune-checkpoint inhibitor therapy).
-
The UCLH Department of Rheumatology is a UK centre of excellence for clinical care, training and research.
-
This leaflet explains the support a transition coordinator at the Adolescent Rheumatology Department provides, and how they can help.
-
This page is for children and young people receiving Proton beam therapy. It explains what growth monitoring is and why it is important.
-
This page has been written for parents and carers whose child is having a single fraction (one treatment) total body irradiation (TBI) for a benign (non-cancerous) blood disorder such as sickle cell anaemia, aplastic anaemia, thalassaemia, or some other condition.
-
This page explains what spasticity is. It contains information on botulinum toxin and its use to treat conditions such as spasticity and dystonia which can occur after a stroke or brain injury.
-
This page explains the use of botulinum toxin in the management of facial weakness and synkinesis as part of treatment process in the complex facial clinic.
-
The special haematology service provides a comprehensive investigation of haemolytic amaemia, haemoglobinopathies and red cell enzymopathy.
File results
-
FOI/2023/0299 - Trust Medical Examiner contact details
-
FOI/2023/0303 - Sexual harassment from patients towards staff in 2022
-
FOI/2023/0305 - Trust held non-pharmaceutical consignment stock holding
-
FOI/2023/0308 - Treatment for biologic and biosimilar products within rheumatology
-
FOI/2023/0310 - Biologic treatment/ medicines in dermatology
-
FOI/2023/0323 - Medications/ treatment for dermatology and respiratory medicine
-
FOI/2023/0338 - Individuals with a change to a gene called CACNA1C for 2021 and 2022
-
FOI/2023/0340 - NHS charging of overseas visitors
-
FOI/2023/0341 - Senior staff contact details
-
FOI/2023/0343 - Clinical guidelines - group B Streptococcus for antenatal, intrapartum and postnatal care